These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Insulin requirement after a renal transplant in patients with type 2 diabetes: the choice of calcineurin inhibitors. van den Hoogen MW, van der Hoeven AM, Hilbrands LB. Exp Clin Transplant; 2013 Jun; 11(3):234-8. PubMed ID: 23432070 [Abstract] [Full Text] [Related]
13. Renal function and cardiovascular risk profile after conversion from ciclosporin to tacrolimus: prospective study in 80 liver transplant recipients. Beckebaum S, Klein C, Varghese J, Sotiropoulos GC, Saner F, Schmitz K, Gerken G, Paul A, Cicinnati VR. Aliment Pharmacol Ther; 2009 Oct 15; 30(8):834-42. PubMed ID: 19624550 [Abstract] [Full Text] [Related]
14. Changes in oxidative stress in renal graft patients receiving calcineurin inhibitors: cyclosporine versus tacrolimus. Akbasli AC, Keven K, Erbay B, Nebioglu S. Exp Clin Transplant; 2012 Oct 15; 10(5):439-45. PubMed ID: 22817282 [Abstract] [Full Text] [Related]
16. Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder. Sarandol A, Sarandol E, Eker SS, Karaagac EU, Hizli BZ, Dirican M, Kirli S. Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug 30; 30(6):1103-8. PubMed ID: 16716479 [Abstract] [Full Text] [Related]
17. Cardiovascular risk profile after conversion from cyclosporine A to tacrolimus in stable renal transplant recipients. Baid-Agrawal S, Delmonico FL, Tolkoff-Rubin NE, Farrell M, Williams WW, Shih V, Auchincloss H, Cosimi AB, Pascual M. Transplantation; 2004 Apr 27; 77(8):1199-202. PubMed ID: 15114085 [Abstract] [Full Text] [Related]